Scancell

Second collaboration for AvidiMab platform

16 December 2019

- Scancell has signed a collaboration and non-excusive research agreement with a Chinese biotechnology company for its AvidiMab monoclonal antibody (mAb) platform. The un-named partner will conduct preclinical studies to evaluate Scancell's anti-TaG mAbs, including those enhanced with AvidiMab, for the treatment of various forms of cancer.
- The AvidiMab technology platform includes a panel of monoclonal antibodies that selectively bind to glycans (carbohydrates on proteins or lipids). Tumour-associated glycans (TaGs) are an attractive, but virtually untapped, pool of oncology targets as they are often highly tumour-specific. The platform offers the potential to create antibodies that kill tumours directly, without the intervention of the immune system; which could be particularly valuable in patients with "cold" tumours.
- Scancell acquired the core of AvidiMab and the IP connected in April 2018 from Nottingham University. It has since strengthened the data package around both the antibodies and the AvidiMab platform itself, with greater preclinical validation of their potential and additional IP.
- The AvidiMab platform was described in an Update note (September 2019) when the first collaboration was announced.

Trinity Delta view: We view licensing deals for the glycan antibodies and AvidiMab technology as a potential source of meaningful, non-dilutive funding for Scancell's key technology platforms, ImmunoBody and Moditope. These are the company's main assets and both of these platforms have considerable potential as monotherapy or in combination with checkpoint inhibitors, based on preclinical data and initial clinical data with SCIB1, and the data from the upcoming trials will provide a better indication of their true potential.

We maintain our valuation based on a rNPV and sum-of-the-parts methodology at £82.0m or 17.2p/share.

Price	4.9p
Market Cap	£22.8m
Primary exchange	AIM
Sector	Healthcare
Company Code	SCLP.L
Corporate client	Yes

Company description:

Scancell is a clinical-stage immuno-oncology specialist that is developing two innovative and flexible therapeutic vaccine platforms. ImmunoBody and Moditope induce high avidity cytotoxic CD8 and CD4 responses, respectively, with the potential to treat various cancers.

Analysts

Mick Cooper
mcooper@trinitydelta.org
+44 (0) 20 3637 5042

Lala Gregorek
lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Mick Cooper mcooper@trinitydelta.org
+44 (0) 20 3637 5042

Lala Gregorek lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Franc Gregori fgregori@trinitydelta.org
+44 (0) 20 3637 5041

Disclaimer

More information is available on our website: www.trinitydelta.org